Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEA 2180 BR in COPD
NCT00122434Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2005
- Primary completion
- May 2006
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of olodaterol in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Trough forced expiratory volume in 1 second response at 4 weeks. Started Jul 2005; status: completed.
02
Drugs
olodaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00122434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00122434.